Stimulation of eosinophil IgE low-affinity receptor leads to increased adhesion molecule expression and cell migration

S. Lantero*, G. Alessandri**, D. Spallarossa*, L. Scarso***, G.A. Rossi*

Stimulation of eosinophil IgE low-affinity receptor leads to increased adhesion molecule expression and cell migration. S. Lantero, G. Alessandri, D. Spallarossa, L. Scarso, G.A. Rossi. ©ERS Journals Ltd 2000.

ABSTRACT: Immunoglobulin binding on eosinophil surface receptors results in activation of these cells. Evaluating blood eosinophils from atopic subjects, it was investigated whether ligation of immunoglobulin E low-affinity receptor (FcεRII/CD23) with specific monoclonal antibodies (Mabs) resulted in enhanced eosinophil migration and adhesion molecule expression.

Eosinophils from 20 subjects with allergic asthma (atopic individuals) and nine nonatopic normal individuals (controls) were purified using Percoll gradients. The effect of antihuman CD23 Mabs on: 1) eosinophil migration through human umbilical vein endothelial cells (HUVECs); and 2) eosinophil expression of the adhesion molecules leukocyte function-associated antigen-1 (LFA-1, CD11a/CD18), macrophage antigen-1 (Mac-1, CD11b/CD18) and very late activation antigen-1 (VLA-4, CD49d/CD29) was evaluated by specific Mab staining and flow cytometric analysis.

As compared to controls, freshly isolated eosinophils from atopic individuals showed enhanced migration through HUVECs (p < 0.05) and increased LFA-1 expression (p < 0.01), but similar Mac-1 and VLA-4 expression (p > 0.1 for both). In both controls and atopic individuals, eosinophil incubation with antihuman CD23 Mabs induced a dose-dependent increase in cell migration through HUVECs, significant at antihuman CD23 Mab concentrations of 5 µg·mL⁻¹ (p < 0.05 for all). Similarly, incubation of the cells with antihuman CD23 Mabs induced dose-dependent upregulation of LFA-1 and Mac-1 expression, whereas no changes in VLA-4 expression were observed (p > 0.1). Finally, the enhanced eosinophil migration induced by antihuman CD23 Mab stimulation was significantly inhibited by antihuman LFA-1 (84±14% (means±SEM); p < 0.01) and VLA-4 Mabs (47±15%; p < 0.05) but not by antihuman Mac-1 Mabs (p > 0.1).

In both atopic and control subjects, immunoglobulin E, low-affinity receptor stimulation induces functional changes in eosinophils characterized by increased eosinophil migration associated with enhanced late function antigen-1 and Mac-1 expression.


In allergic asthma, exposure to the sensitizing allergen leads to eosinophil recruitment and activation. Eosinophils have the potential to injure human lung tissues and their presence in the airway mucosa has been associated with degree of airflow limitation and morphological derangement of the bronchial epithelium. The current thought is, therefore, that eosinophils act as major effector elements in the pathogenesis of allergic asthma [1, 2].

Eosinophil recruitment is a complex mechanism, which includes the expression of surface adhesion molecules on circulating cells, able to interact with their counter-receptors, expressed on vascular endothelial cells [3]. It has been demonstrated that T-helper 2 (Th2) cytokines (interleukin (IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor) and chemokines (eotaxin and regulated on activation, normal T-cell expressed and secreted) are able to not only prime and activate eosinophils but also increase cell receptor and adhesion molecule expression on these cells [3–7]. In atopic asthma, a condition characterized by increased secretion of Th2 cytokines and chemokines, the expression of adhesion molecules on the eosinophil cell membrane is increased and appears to be involved in cell migration [8].

Besides inflammatory mediators, stimulation of surface receptors specific for immunoglobulins (Igs) also plays a significant role in modulating cell function [9, 10]. Eosinophils are able to bind IgE through high- and low-affinity receptors (FcεRI and FcεRII or CD23 respectively) [11, 12], and, although the specific functions of FcεRI and FcεRII are still controversial [10, 12], it has been demonstrated that anti-CD23 monoclonal antibodies (Mabs) or IgE/anti-IgE immune complexes are able to increase hydrogen peroxide and tumour necrosis factor production by eosinophils [9]. The observation that allergic patients with a high level of allergen-specific IgE show increased expression of eosinophil adhesion molecules and the reported correlation between serum allergen-specific IgE, the number of
Eosinophils infiltrating the airways and the severity of asthma [8] suggest that FcεRII may modulate eosinophil locomotion. Against this background, the present study was designed to evaluate in vitro whether stimulation of the FcεRII by antihuman CD23 Mabs enhanced eosinophil migration through human umbilical vein endothelial cells (HUVECs) and expression of the adhesion molecules leukocyte function-associated antigen-1 (LFA-1, CD11a/CD18), macrophage antigen-1 (Mac-1, CD11b/CD18) and very late antigen-1 (VLA-4, CD49d/CD29) involved in eosinophil transendothelial migration.

Materials and methods

Reagents

Complete medium comprised Roswell Park Memorial Institute (RPMI)-1640 medium (PAA, Linz, Austria), 50 U·mL⁻¹ penicillin, 50 mg·mL⁻¹ streptomycin, 2 mM l-glutamine, 2 mg·mL⁻¹ NaHCO₃, 1 × nonessential amino acids, 5% foetal calf serum (FCS) (Flow ICN, Irvine, UK) and 2 mM 2-mercaptoethanol (Sigma Chemical Co., St Louis, MO, USA). Endothelial basal medium (EBM) was obtained from Dilco Laboratories (Milan, Italy). Trypan blue and phosphate-buffered saline (PBS) were from Flow ICN Dextran (molecular weight 70,000), 10 × Hank's balanced salt solution (HBSS), sodium azide and complement factor 5α (C5α) were obtained from Sigma Chemical Co. Heparin was from Parke-Davis S.p.A. (Milan, Italy), Percoll from Pharmacia (Uppsala, Sweden), and Diff-Quik from Merz+Dade (Dudingen, Switzerland). Mouse antihuman IgG1 Mab to CD23 and CD45; mouse antihuman IgG1 Mabs to CD23 and CD45; mouse antihuman IgG1 Mab to CD11a, conjugated to R-phycoerythrin (PE) and unconjugated, were obtained from Serotec (Oxford, UK), mouse antihuman IgG1 Mab to CD11b, and CD49d, both PE-conjugated and unconjugated, were obtained from Serotec. Mouse antihuman IgG1 Mab to CD11a, conjugated to R-phycoerythrin (PE) and unconjugated (clone B-B15); mouse antihuman IgG1 to CD3 PE-conjugated and unconjugated, as isotype control; and antihuman CD11b, and CD49d, both PE-conjugated and unconjugated, were obtained from Serotec (Oxford, UK), mouse antihuman IgG1 Mab to CD16b conjugated to fluorescein isothiocyanate from Ortho Diagnostic System (Milan, Italy) and PE-conjugated mouse antihuman IgG1 Mab to CD23 from Becton Dickinson (Milan, Italy).

Population

Eosinophils were obtained from nine nonatopic normal individuals (controls) (6–11 yrs; seven male and two female) and 20 atopic asthmatic subjects sensitized to house dust mites, as demonstrated by skin-prick test and radioallergosorbent test (Pharmacia) (atopic individuals) (6–14 yrs; 15 male and 5 female) (table 1). Asthma was defined according to the criteria of the American Thoracic Society [13]. Controls and atopic individuals had not suffered from respiratory infections in the previous 4 weeks and were not under any treatment other than β₂-stimulants on an "as necessary" basis. The study was approved by the G. Gaslini Institute Ethical Committee and parents or tutors of all subjects gave their informed consent.

Because of the relatively high numbers of cells required, eosinophils collected from different individuals were often used to perform different kinds of experiment, as indicated below.

![Table 1. – Characteristics of atopic individuals and controls](image)

<table>
<thead>
<tr>
<th>Subject No.</th>
<th>Sex</th>
<th>Age</th>
<th>Eosinophils %</th>
<th>PRIST kU·L⁻¹</th>
<th>RAST kU·L⁻¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>6</td>
<td>1.7</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>6</td>
<td>1.8</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>6</td>
<td>2.1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>6</td>
<td>1.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>11</td>
<td>3.2</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>6</td>
<td>2.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>8</td>
<td>0.9</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>6</td>
<td>2.7</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>9</td>
<td>5.4</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atopic individuals*</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>6</td>
<td>4.8</td>
<td>165</td>
<td>76.1</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>6</td>
<td>4.8</td>
<td>1431</td>
<td>&gt;100</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>6</td>
<td>3.9</td>
<td>210</td>
<td>33.6</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>6</td>
<td>4.8</td>
<td>115</td>
<td>49.5</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>6</td>
<td>6.2</td>
<td>602 &gt;100</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>10</td>
<td>8.9</td>
<td>316</td>
<td>67.0</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>6</td>
<td>10.9</td>
<td>381 &gt;100</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>6</td>
<td>6.4</td>
<td>240 &gt;100</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>11</td>
<td>6.0</td>
<td>405 &gt;100</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>8</td>
<td>14.8</td>
<td>411</td>
<td>59.5</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>7</td>
<td>11.4</td>
<td>290</td>
<td>63.0</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>14</td>
<td>19.2</td>
<td>857 &gt;100</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>9</td>
<td>4.3</td>
<td>465</td>
<td>61.4</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>12</td>
<td>5.7</td>
<td>580</td>
<td>13.9</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>8</td>
<td>13.0</td>
<td>1842 &gt;100</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>12</td>
<td>6.5</td>
<td>323</td>
<td>82.1</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>6</td>
<td>11.4</td>
<td>504 &gt;100</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>12</td>
<td>2.4</td>
<td>158</td>
<td>76.4</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>6</td>
<td>6.3</td>
<td>290</td>
<td>58.3</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>6</td>
<td>4.1</td>
<td>471</td>
<td>59.4</td>
</tr>
</tbody>
</table>

*: atopic individuals but not controls were sensitized to house dust mites. SPT: skin-prick test; RAST: radioallergosorbent test; M: male; F: female; PRIST: paper radio immunosorbent test.

**Eosinophil purification**

Isolation of blood eosinophils was performed on discontinuous Percoll gradients, as previously described [14]. Briefly, to 10 mL heparinized blood, an equal volume of 6% dextran in 0.9% NaCl was added, mixed gently and incubated at 37°C. After 30–40 min, the upper phase was collected, washed once in PBS, resuspended in 1.5 mL 1.070 g·mL⁻¹ Percoll containing 5% FCS and layered on a discontinuous Percoll gradient with the following volumes (mL) and densities (g·mL⁻¹) respectively: 1.5, 1.100; 3, 1.090; 3, 1.085; and 3, 1.080 [14]. The Percoll gradient densities were obtained by mixing nine parts of Percoll with one part of 10×HBSS and then diluting the 90% Percoll solution with 1×HBSS containing 5% FCS. The normodense eosinophils recovered from 1.090–1.095 g·mL⁻¹ Percoll were washed twice in PBS and resuspended at 1×10⁶ eosinophils·mL⁻¹ in complete medium. The hypodense population represented only a small proportion of the total eosinophil population and, because of the low number of cells, could not be used to perform any study. The eosinophils recovered were 70–80% pure (as established by Diff-Quik staining, with neutrophils as contaminant) and 90% viable, as determined by trypan blue dye exclusion test.
Evaluation of eosinophil migration through endothelial cell layer

The day before the assay, 5 × 10⁶ HUVECs were seeded on polycarbonate membranes with 8-μm pores coated with type I collagen, in order to reach confluence on the day of the assay, and incubated in EBM under 5% CO₂ conditions at 37°C [15]. On the day of the assay, the membranes were placed in Boyden chemotaxis chambers with the HUVEC side up. The lower wells were filled with 50 μL complete medium, to evaluate random migration, or with 0.1 μg-mL⁻¹ C5a in complete medium, as eosinophil chemoattractant [16]. The C5a concentration had been established in previous dose/response experiments on eosinophils from both controls and atopic individuals. Unstimulated or CD23-stimulated eosinophils (see below) in 100 μL complete medium at a concentration of 1 × 10⁶ cells·mL⁻¹ were seeded in the upper chamber compartments, on the HUVEC side. After a 3-h incubation under 5% CO₂ conditions at 37°C, the membranes were detached, the HUVECs peeled off the upper side and the eosinophils that had migrated through the HUVECs to the lower side were fixed, stained with Diff-Quick and counted using a light microscope. All the chemotactic conditions were tested in duplicate and the data expressed as number of eosinophils migrated in 10 high-power fields (HPFs, magnification ×400) [16].

Evaluation of membrane molecule expression on eosinophils

LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18), VLA-4 (CD49d/CD29) and FcεRII (CD23) expression on eosinophils from controls and atopic individuals was evaluated by staining with specific Mabs and flow cytometry. Cells were washed once in PBS, resuspended in 100 μL PBS containing 2% FCS and 0.5 μg·mL⁻¹ NaN₃ (staining medium), and stained with 10 μg·mL⁻¹ FITC-conjugated antihuman CD16b (green fluorescence, to distinguish by two-colour flow cytometry contaminant CD16b⁺ neutrophils from CD16b⁻ eosinophils), [4] and 10 μg·mL⁻¹ PE-conjugated antihuman CD11a, CD11b, CD49d, CD23 or CD3 (mouse IgG isotype control) (red fluorescence). In order to test the possibility that the process of eosinophil separation could increase the expression of some membrane receptors detected by flow cytometry [17], whole-blood staining was also performed in five atopic individuals and in three controls. Unstimulated or CD23-stimulated eosinophils (see below) were then incubated for 1 h at 4°C, washed twice in staining medium and resuspended at 5 × 10⁵ cells·mL⁻¹ in 200 μL PBS.

The red fluorescence intensity of the CD16b⁻ cells (eosinophils) was obtained for 10,000 acquired cells using flow cytometry (FACSScan; Becton Dickinson, Milan, Italy) and expressed as mean fluorescence channel (MFC) [18]. To compare the fluorescence intensity of different samples, the cells were acquired under identical logarithmic amplifier settings and analysed using Lysis II software (Becton Dickinson). After conversion to linear fluorescence intensity units the mean background obtained using the control antibody (PE-conjugated antihuman Mab to CD3) was subtracted from the mean fluorescence intensity of the specifically stained cells to obtain a linear function of fluorescence intensity over a wide range [19].

Eosinophil stimulation by immunoglobulin E low-affinity receptor ligation with antihuman monoclonal antibody to CD23

Eosinophils from eight controls and 14 atopic individuals were resuspended in complete medium, seeded in 96-well U-bottomed plates (Costar, Cambridge, MA, USA) in a total volume of 100 μL at 10⁶ eosinophils·mL⁻¹. Flow cytometry on CD23-stained eosinophils was performed before the assays to demonstrate the expression of FcεRII on eosinophils of all subjects who were the source of cells for these experiments. Preliminary sets of experiments demonstrated that the length of time required to detect antihuman Mab to CD23-induced modification of adhesion molecule expression on eosinophils was ~3 h. The cells were, therefore, incubated with different concentrations of antihuman CD23 (0.5, 2.5, 5, 10 or 20 μg·mL⁻¹) or, as control, antihuman Mab to CD45, which recognizes all leukocytes for 3 h under 5% CO₂ conditions at 37°C. After incubation, chemotactic activity and expression of adhesion molecules were evaluated as described above. To evaluate the functional role of the different adhesion molecules in cell migration, eosinophils were preincubated in the presence or absence of antihuman Mabs to CD11a, CD11b or CD49d or mouse IgG, as isotype control, (10 μg·mL⁻¹) for 30 min under 5% CO₂ conditions at 37°C prior to the chemotaxis assay.

Statistical analysis

Data are expressed as mean±SEM. Statistical comparisons between different cell culture conditions were performed using an unpaired t-test or the Mann-Whitney U-test, when appropriate [20]. Data were considered significant at a p-value of <0.05.

Results

Eosinophil migration through human umbilical vein endothelial cells and adhesion molecule expression

In both controls and atopic individuals, C5a significantly enhanced eosinophil locomotion above random migration levels. However, as compared to controls, eosinophils from atopic individuals showed greater migration through HUVECs towards C5a (16±4 versus 22±4 eosinophils·10 HPF⁻¹, p<0.05) (fig. 1a). In addition, as compared to controls, increased membrane expression of LFA-1 was detected on eosinophils from atopic individuals (33±6 versus 62±5 MFC, p<0.01), whereas there were no difference in the expression of Mac-1 and VLA-4 (p>0.1) (fig. 1b). No staining was observed with the mouse IgG isotype control (data not shown). The process of eosinophil separation did not appear to influence the expression of adhesion molecules, since no differences in the levels of LFA-1, Mac-1 and VLA-4 expression were found when eosinophils in unseparated whole-blood samples or after discontinuous Percoll gradient separation, in both atopic individuals and controls (p>0.1 for both), were evaluated (data not shown).
Immunoglobulin E low-affinity receptor ligation activity on eosinophils

All of the atopic individuals and most of the controls (six of nine) expressed low but detectable levels of CD23 (p<0.05 for both versus CD3, the isotype control). The mean expression level was slightly but not significantly higher in atopic individuals compared to controls (p>0.1) (fig. 2). Incubation of eosinophils with antihuman Mabs to CD23 induced a dose-dependent increase in cell migration towards 0.1 µg·mL⁻¹ C5a in both controls and atopic individuals. In contrast, no changes in cell locomotion through HUVECs were detected when eosinophils were cultured in the presence of the control antihuman Mabs to CD45 (p>0.05 for all) (fig. 3). The increase in cell migration induced by antihuman Mabs to CD23 reached statistical significance at Mab concentrations of 5 µg·mL⁻¹ in both controls (p<0.01) and atopic individuals (p<0.05). Interestingly, eosinophil stimulation with the antihuman Mab to CD23 also induced a dose-dependent increase in LFA-1 and Mac-1 expression, but not in VLA-4 expression (p>0.1), in both controls and atopic individuals, whereas no changes were detected in the presence of the control antihuman Mabs to CD45 (p>0.05 for all) (fig. 4).
antihuman Mab to CD23-induced increase in LFA-1 expression reached statistical significance at Mab concentrations of 5 \( \mu \)g \cdot mL\(^{-1} \) in atopic individuals and of 10 \( \mu \)g \cdot mL\(^{-1} \) in controls (fig. 4a and d). The increase in Mac-1 expression reached statistical significance at Mab concentrations of 10 \( \mu \)g \cdot mL\(^{-1} \) in both atopic individuals and controls (figs. 4b and e).

Adhesion receptor activity and eosinophil migration through human umbilical vein endothelial cells

In order to evaluate the functional role of the different adhesion molecules in modulating cell migration, CD23-stimulated eosinophils from five atopic individuals were preincubated with blocking Mabs directed against LFA-1 (CD11a), Mac-1 (CD11b) or VLA-4 (CD49d), or with a mouse IgG, as isotype control, and tested in the chemotaxis assay using C5a as chemotactic agent. Eosinophil migration through HUVECs was totally inhibited by anti-human Mabs to CD11a (28.4 ± 6.2 eosinophils \cdot 10\(^{-3} \) HPF\(^{-1} \) versus controls (fig. 4a and c), and only partially by antihuman Mabs to CD49 (28.4 ± 6.2 eosinophils \cdot 10\(^{-3} \) HPF\(^{-1} \), p<0.05), whereas antihuman Mabs to CD11b had no modifying effect on cell locomotion (p>0.1) (fig. 5).

Discussion

Evaluating partially purified blood eosinophils in vitro, it was demonstrated that unstimulated cells from atopic asthmatic subjects show a significantly higher cell migration rate and increased expression of LFA-1 compared to eosinophils from controls. No differences in Mac-1 or VLA-4 expression were observed. Eosinophils from most controls and all atopic individuals showed similar CD23 expression by fluorescence-activated cell sorting (FACS) analysis, and cell stimulation with anti-IgE low-affinity receptor Mabs enhanced, in a dose-dependent manner, eosinophil migration through HUVECs and LFA-1 and Mac-1 (but not VLA-4) expression in both controls and atopic individuals. Finally, eosinophil migration through HUVECs was totally inhibited by the antihuman Mabs to LFA-1 and partially by the antihuman Mabs to VLA-4.

The finding that eosinophil migration and LFA-1 expression were increased in atopic asthmatic subjects is consistent with previous reports and with the concept that "preactivation" of circulating polymorphonuclear leukocytes occurs in allergic asthma [21, 22]. These biological properties of circulating eosinophils may, at least partially, explain the substantial migration of these cells into target tissue that occurs during acute asthma attacks and shortly after natural or experimental allergen exposure [23].

Cytokines and chemokines are able to preactivate eosinophils and increase adhesion molecule expression and cell locomotion [3–7]. In the present study it was also demonstrated that stimulation of FceRII, with antihuman Mabs to CD23 enhanced eosinophil migration through HUVECs and adhesion molecule (LFA-1 and Mac-1) expression.

Although eosinophils also display other IgE receptors, such as FceRI and Mac-2/\( \beta \)p, it appears that many IgE-induced eosinophil functions are mediated mainly by
Fc γ
ein endothelial cells towards 0.1
role of Fc γ
specific IgE [8] further supports the hypothesis of a
disease severity and to higher serum levels of allergen-
VLA-4 but not Mac-1 is involved in eosinophil trans-
the experiments performed in the present study
in VLA-4, the experiments performed in the present study
LFA-1 and Mac-1 adhesion molecule expression, but not
CD23 and incubated with different blocking Mabs. Data are presented as
molecules expressed but also to their biological properties
functions are related not only to the "amounts" of
demonstrated for other surface molecules, receptor
response effect of CD23 stimulation on both eosinophil
experiments; these responded in a dose-dependent manner
Activation in processes that follow transendothelial migration,
which is specifically involved in eosinophil migration
through the endothelium [25, 26] whereas VLA-4 appears
to mainly determine the initial adherence process to the
vessel wall, allowing the cells to slow down in the bloodstream [27, 28]. Mac-1 was not efficient in the
present experimental system in mediating eosinophil
transendothelial migration. Indeed, the demonstration
that, in asthmatic patients, Mac-1 expression is increased
in bronchial eosinophils, as compared to blood eosino-
from the same subjects [29], suggests its involve-
ment in processes that follow transendothelial migration,
e.g. interaction with other airway cells in the tissues.
Adhesion mechanisms can be upregulated through
increased molecule expression on the cell membrane or
through conversion of the molecule from a "low" to a
"high" avidity state.
Modifications of LFA-1 and Mac-1 expression, obser-
ed in the present study following FcγRII stimulation,
appear to be related, at least in part, to increased molecular
density on the cell membrane. These changes were
detected by flow cytometry 2–4 h after stimulation, a
period of time typical of that required for the regulation of
surface adhesion receptor density at the messenger
ribonucleic acid level [28, 30]. In addition to increased
molecular density, qualitative changes in adhesion mole-
cule function, which occur on a much shorter timescale
(minutes), could also be involved in the observed en-
hancement of eosinophil migration through HUVECs [28, 30].
In summary, in both atopic and control subjects, the
functional presence of immunoglobulin E low-affinity
receptor on blood eosinophils and its involvement in
regulating the transendothelial trafficking of eosinophils
was demonstrated.

References
7. Ehsaisawa M, Yamada T, Bickel C, Klink D, Shleimer RP. Eosinophil transendothelial migration induced by cyto-


